Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.53 |
| ▸ | SRC | P12931 | 5/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.53 |
| ▸ | WEE1 | P30291 | 7/20 | 0.53 |
| ▸ | PLK1 | P53350 | 3/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609444 | 0.93 | WEE1 (0.52) | LCKSRCKDRWEE1PLK1 | |
| SCHEMBL9609451 | 0.92 | WEE1 (0.51) | LCKSRCKDRWEE1PLK1 | |
| SCHEMBL9610722 | 0.91 | WEE1 (0.49) | LCKSRCKDRWEE1PLK1 | |
| SCHEMBL9610753 | 0.91 | WEE1 (0.55) | LCKSRCKDRWEE1PLK1 | |
| SCHEMBL8509592 | 0.90 | WEE1 (0.55) | WEE1PLK1FLT3 | |
| SCHEMBL9609446 | 0.90 | WEE1 (0.52) | LCKSRCKDRWEE1PLK1 | |
| SCHEMBL8510413 | 0.90 | WEE1 (0.51) | LCKSRCKDRWEE1PLK1 | |
| SCHEMBL9609445 | 0.90 | WEE1 (0.49) | LCKSRCKDRWEE1PLK1 | |
| SCHEMBL8514394 | 0.90 | WEE1 (0.51) | LCKSRCKDRWEE1PLK1 | |
| SCHEMBL9609452 | 0.90 | WEE1 (0.54) | LCKSRCKDRWEE1PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | LCK 540/4885SRC 546/4885KDR 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.